Physicochemical and Biological Examination of Two Glatiramer Acetate Products.
- Published in:
- Biomedicines, 2019, v. 7, n. 3, p. 49, doi. 10.3390/biomedicines7030049
- By:
- Publication type:
- Article
Works matching DE "MYLAN NV"
Results: 21
1
2
THE UNTOLD EPIPEN STORY: HOW MYLAN HIKED PRICES BY BLOCKING RIVALS.
- Published in:
- Cornell Law Review, 2017, v. 102, n. 3, p. 53
- By:
- Publication type:
- Article
3
Pfizer to collaborate with Mylan to develop and market Generics in Japan.
- Published in:
- Pulse International, 2012, v. 13, n. 18, p. 8
- Publication type:
- Article
4
Supply sorted.
- Published in:
- Chemistry & Industry, 2019, v. 83, n. 3, p. 40, doi. 10.1002/cind.833_14.x
- By:
- Publication type:
- Article
5
MYLAN’S PRICE HIKE OF EPIPENS: HOLDING THE PHARMACEUTICAL GIANT ACCOUNTABLE.
- Published in:
- Gonzaga Law Review, 2016, v. 52, n. 3, p. 587
- By:
- Publication type:
- Article
6
Patent watch.
- Published in:
- Nature Reviews Drug Discovery, 2010, v. 9, n. 11, p. 832, doi. 10.1038/nrd3312
- By:
- Publication type:
- Article
7
Manipulating the Prescription Drug Market: Spiking Prices, Inducing Demand, and Costs to the Public.
- Published in:
- DePaul Journal of Health Care Law, 2022, v. 23, n. 2, p. 20
- By:
- Publication type:
- Article
8
SOLIDARISM AND THE EPIPEN.
- Published in:
- Ethics & Medics, 2017, v. 42, n. 2, p. 3, doi. 10.5840/em20174224
- By:
- Publication type:
- Article
9
Shock to the System: How Alternative Dispute Resolution Can Foster Change in the Price-Setting of Mylan's EpiPen.
- Published in:
- Ohio State Journal on Dispute Resolution, 2018, v. 33, n. 2, p. 255
- By:
- Publication type:
- Article
10
LB3. Exebacase (EXE) Reduced Length of Stay and 30-Day Readmission Rates for US Patients with Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia Including Endocarditis Compared with Standard of Care Antibiotics (SoC) Alone in a Phase 2 Study.
- Published in:
- Open Forum Infectious Diseases, 2019, v. 6, p. S994, doi. 10.1093/ofid/ofz415.2486
- By:
- Publication type:
- Article
11
AstraZeneca in a fix over prosilec protection.
- Published in:
- Chemistry & Industry, 2003, n. 16, p. 7
- Publication type:
- Article
12
Capitol Health Call.
- Published in:
- JAMA: Journal of the American Medical Association, 2016, v. 316, n. 14, p. 1439
- By:
- Publication type:
- Article
13
Is It Time for the USPSTF to Inform-But Not Determine-Coverage?
- Published in:
- 2016
- By:
- Publication type:
- journal article
14
Silymarin in non-cirrhotics with non-alcoholic steatohepatitis: A randomized, double-blind, placebo controlled trial.
- Published in:
- PLoS ONE, 2019, v. 14, n. 9, p. 1, doi. 10.1371/journal.pone.0221683
- By:
- Publication type:
- Article
15
Biocon, Mylan in pan-biogenerics deal.
- Published in:
- Nature Biotechnology, 2009, v. 27, n. 9, p. 786, doi. 10.1038/nbt0909-786b
- By:
- Publication type:
- Article
16
Ethical Concerns Regarding Rise in EpiPen Price.
- Published in:
- Penn Bioethics Journal, 2017, v. 12, n. 2, p. 10
- Publication type:
- Article
17
In-store this month.
- Published in:
- 2017
- Publication type:
- Product Review
18
Ethical drug updates: The latest drug announcements and PBS listings.
- Published in:
- 2017
- Publication type:
- Product Review
19
In-store this month: The latest products available in pharmacy...
- Published in:
- 2017
- Publication type:
- Product Review
20
In-store this month.
- Published in:
- 2017
- Publication type:
- Product Review
21
Ethical drug updates.
- Published in:
- 2016
- Publication type:
- Product Review